Diálisis y Trasplante最新文献

{"title":"Cuarto informe del Presidente (SEDYT 2011-2015)","authors":"Julen Ocharan-Corcuera","doi":"10.1016/j.dialis.2015.05.001","DOIUrl":"10.1016/j.dialis.2015.05.001","url":null,"abstract":"","PeriodicalId":100373,"journal":{"name":"Diálisis y Trasplante","volume":"36 2","pages":"Pages 45-47"},"PeriodicalIF":0.0,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.dialis.2015.05.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86157257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consumo de C3 como única manifestación de nefropatía lúpica v/iii en paciente varón con síndrome nefrótico. Caso clínico y revisión corta","authors":"Juan Vladimir Pérez-Tinoco ,&nbsp;Claudia Ivett Rios-Zarate ,&nbsp;M. Virgilia Soto-Abraham ,&nbsp;Pedro López-Vazquez","doi":"10.1016/j.dialis.2015.02.005","DOIUrl":"10.1016/j.dialis.2015.02.005","url":null,"abstract":"<div><p>Systemic Lupus Erythematosus (SLE) is an autoimmune chronic disease that causes potentially systemic injury or/and inflammation. We report a case of a 18 year old Mexican man; presenting with serum creatinine elevation in a routine laboratories without any symptoms. We only found C3 alterations at the initial study. We provide a review of the literature describing Systemic lupus erythematosus characteristics.</p></div>","PeriodicalId":100373,"journal":{"name":"Diálisis y Trasplante","volume":"36 2","pages":"Pages 83-86"},"PeriodicalIF":0.0,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.dialis.2015.02.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78952757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Agradecimiento a revisores 2014","authors":"","doi":"10.1016/j.dialis.2015.03.001","DOIUrl":"https://doi.org/10.1016/j.dialis.2015.03.001","url":null,"abstract":"","PeriodicalId":100373,"journal":{"name":"Diálisis y Trasplante","volume":"36 1","pages":"Page 43"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.dialis.2015.03.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136827652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Terapia renal en pacientes con fracaso renal agudo en Unidad de Cuidados Intensivos, terapia de reemplazo renal continua, intermitente prolongada e intermitente: estudio de supervivenci","authors":"L.M. Rizo-Topete,&nbsp;M. Arellano-Torres,&nbsp;J. Hernández-Portales,&nbsp;R. Treviño-Frutos,&nbsp;R. Monreal-Puente","doi":"10.1016/j.dialis.2014.10.002","DOIUrl":"10.1016/j.dialis.2014.10.002","url":null,"abstract":"<div><h3>Background</h3><p>Acute kidney injury (AKI) is a common complication in hospitalized patients, and is an independent predictor of mortality. Approximately 4-5% of patients in ICU will need renal replacement therapy (RRT), and more than two-thirds of these patients will develop AKI, with a mortality of 50 to 60%. Although continuous renal replacement therapy (CRRT) is the preferred treatment in patients with AKI in ICU, especially if there is hemodynamic instability, no differences in survival compared to intermittent hemodialysis (IHD) or hybrid therapies, such as prolonged intermittent renal replacement therapies (PIRRT), have been demonstrated.</p></div><div><h3>Objective</h3><p>To describe our experience with different renal replacement therapies and the survival of our patients.</p></div><div><h3>Hypothesis</h3><p>There is no difference in short-term survival between patients with AKI or acute chronic disease who required RRT, such as CRRT or hybrid therapy, than those who were treated using intermittent hemodialysis (IHD).</p></div><div><h3>Methods</h3><p>A retrospective study was conducted from March 2009 to June 2012 on all patients who were treated with RRT in ICU, with survival being assessed after 28 days follow-up.</p></div><div><h3>Results and conclusions</h3><p>The study included a total of 33 patients, of whom 20 were male and 13 females. They were divided into therapy groups, with 21 for CRRT, 6 for hybrid therapies, and 6 de IHD. The percentage survival was 28.6% for CRRT, 16.7% for hybrid, and 33.3% for IHD.</p><p>It could not be demonstrated that there was a greater survival in any of the therapies in this study.</p></div>","PeriodicalId":100373,"journal":{"name":"Diálisis y Trasplante","volume":"36 1","pages":"Pages 8-14"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.dialis.2014.10.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86781391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deterioro de función renal en paciente nefrópata bajo terapia broncodilatadora con bromuro de glicopirronio","authors":"Manuel Heras ,&nbsp;Graciliano Estrada ,&nbsp;María José Fernández-Reyes ,&nbsp;Álvaro Molina ,&nbsp;Ramiro Callejas ,&nbsp;Astrid Rodríguez","doi":"10.1016/j.dialis.2015.02.007","DOIUrl":"10.1016/j.dialis.2015.02.007","url":null,"abstract":"","PeriodicalId":100373,"journal":{"name":"Diálisis y Trasplante","volume":"36 1","pages":"Pages 41-42"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.dialis.2015.02.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78175738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The NT-proBNP: A useful marker of cardiac dysfunction in chronic hemodialysis patients","authors":"Gioacchino Li Cavoli ,&nbsp;Silvia Passanante ,&nbsp;Onofrio Schillaci ,&nbsp;Carmela Zagarrigo ,&nbsp;Franca Servillo ,&nbsp;Tancredi Vincenzo Li Cavoli ,&nbsp;Mattia Palmeri ,&nbsp;Ugo Rotolo","doi":"10.1016/j.dialis.2014.10.001","DOIUrl":"10.1016/j.dialis.2014.10.001","url":null,"abstract":"","PeriodicalId":100373,"journal":{"name":"Diálisis y Trasplante","volume":"36 1","pages":"Page 40"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.dialis.2014.10.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83836571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validez diagnóstica del índice de resistividad en pacientes trasplantados renales con disfunción del injerto: correlación histológica","authors":"Paula García Barquín ,&nbsp;Jon Etxano Cantera ,&nbsp;Maite Millor Muruzabal ,&nbsp;Hernán Dario Quiceno Arias ,&nbsp;David Cano Dafart ,&nbsp;Alberto Benito Boillos","doi":"10.1016/j.dialis.2014.10.003","DOIUrl":"10.1016/j.dialis.2014.10.003","url":null,"abstract":"<div><h3>Objective</h3><p>To estimate the diagnostic validity of the resistance index (RI) in renal transplant patients with graft dysfunction, using the histopathological findings as gold standard.</p></div><div><h3>Material and methods</h3><p>A retrospective review was performed on the biopsies of 85 patients with renal graft dysfunction. Patients were grouped according to the histological findings: normal findings, acute rejection, chronic rejection, and other findings. The RI was assessed by Doppler ultrasound, considering values of<!--> <!-->&lt;<!--> <!-->.55 and<!--> <!-->&gt;<!--> <!-->.75 as pathological, and were analyzed along with the findings in the biopsy. Sensitivity, specificity, positive predictive value and negative predictive value of RI were assessed. The mean RI was compared between patients with normal and abnormal pathological findings.</p></div><div><h3>Results</h3><p>The RI was normal in 59 patients, and pathological in 26. The RI showed a specificity of 72.73% and a high positive predictive value of 88.46% in patients with graft dysfunction. There was no statistically significant difference (<em>P</em> <!-->=<!--> <!-->.196) in the RI between patients with normal and pathological histopathology in the biopsy.</p></div><div><h3>Conclusion</h3><p>Despite its low sensitivity, the RI is reliable in detecting an abnormal parameter when its value is outside the reference range. However the performing a biopsy is still required to determine the cause of the kidney disease.</p></div>","PeriodicalId":100373,"journal":{"name":"Diálisis y Trasplante","volume":"36 1","pages":"Pages 15-19"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.dialis.2014.10.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84138879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"El embarazo en una paciente con enfermedad renal crónica en hemodiálisis: a propósito de un caso y revisión de la literatura","authors":"Nasser Abdel Polanco,&nbsp;Kalid A. Gutiérrez,&nbsp;Nancy Chavero Morales","doi":"10.1016/j.dialis.2014.11.005","DOIUrl":"10.1016/j.dialis.2014.11.005","url":null,"abstract":"<div><p>The case is presented of a pregnant patient at 20 weeks gestation with chronic renal disease in advanced stage and in poor general condition, which required initiation of renal replacement therapy due to uremia and fluid retention. Although her referral was delayed, it was possible to improve her general condition in all aspects, allowing her to have an electively scheduled abdominal birth at 38 weeks, with favorable results for the newborn that exceeded the statistics described in these patients. This case is presented along with a review of the literature and a critical analysis of the management of these patients.</p></div>","PeriodicalId":100373,"journal":{"name":"Diálisis y Trasplante","volume":"36 1","pages":"Pages 34-39"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.dialis.2014.11.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85223194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilidad clínica de la reserva funcional renal","authors":"Daniel Murillo-Brambila ,&nbsp;Fernando Enrique Núñez-Gómez ,&nbsp;Silvia González-Sanchidrián ,&nbsp;María-Jimena Muciño-Bermejo ,&nbsp;Aashish Sharma ,&nbsp;Claudio Ronco","doi":"10.1016/j.dialis.2015.02.004","DOIUrl":"10.1016/j.dialis.2015.02.004","url":null,"abstract":"<div><p>Renal function reserve (RFR) represents the capacity of the kidney to increase glomerular filtration rate (GFR) in response to certain physiological or pathological stimuli or conditions.</p><p>Baseline GFR displays variable values according to the diet or other factors, and may be normal even when there is an important lowering of nephron number. Once baseline GFR is determined, RFR can be assessed clinically by oral protein load or intravenous aminoacid infusion.</p><p>RFR is the difference between peak (stress-induced) GFR and basal GFR. In clinical scenarios where hyper-filtration is present (high baseline GFR due to pregnancy, hypertensive or diabetic nephropathy, solitary kidney or kidney donors) RFR may be fully or partially used to achieve normal or supra-normal renal function.</p><p>RFR test may represent a sensitive and early way to asses kidney functional decline and recovery. In cases of healing with a defect and fibrosis, clinical assessment may suggest a complete recovery, but a reduced RFR may be a sign of a maladaptive repair or sub-clinical loss of renal mass. Therefore, a reduction of RFR may represent the equivalent of renal frailty or susceptibility to insults. The main aim of this article is to review the concept of RFR, its utility in different clinical scenarios and future perspective for its use.</p></div>","PeriodicalId":100373,"journal":{"name":"Diálisis y Trasplante","volume":"36 1","pages":"Pages 27-33"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.dialis.2015.02.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81805936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asociación de simvastatina con ezetimiba como alternativa terapéutica en el control lipídico de enfermos renales crónicos en estadio 3-4. Resultados a un año","authors":"José Luis Merino ,&nbsp;Erika Lozano ,&nbsp;Patricia Domínguez ,&nbsp;Yésika Amézquita ,&nbsp;Blanca Bueno ,&nbsp;Beatriz Espejo ,&nbsp;Vicente Paraíso","doi":"10.1016/j.dialis.2015.02.003","DOIUrl":"10.1016/j.dialis.2015.02.003","url":null,"abstract":"<div><h3>Introduction</h3><p>Maximizing the control of conventional risk factors should be crucial in patients with chronic kidney disease due to their high cardiovascular risk. Recent studies suggest that lipid control using the combination of a statin and ezetimibe may have benefits in this specific population.</p></div><div><h3>Material and methods</h3><p>From September-2011 to September-2014, 22 patients with chronic kidney disease, stage 3-4 who did not reach optimal lipid levels in monotherapy with statin were included in the study. Mean age 67<!--> <!-->±<!--> <!-->8 years. Half of the patients were smokers, 68% were diabetic and all of them received hypertensive treatment.</p></div><div><h3>Results</h3><p>Baseline, 6 months and one year follow-up controls were performed. Total cholesterol mean baseline and at one year was 202<!--> <!-->±<!--> <!-->39<!--> <!-->mg/dl and 147<!--> <!-->±<!--> <!-->38 (<em>P</em>=.001), LDL, HDL and triglycerides baseline and at one year were as follows respectively: 123<!--> <!-->±<!--> <!-->27 vs. 73<!--> <!-->±<!--> <!-->28 (<em>P</em>=.0005), 45<!--> <!-->±<!--> <!-->12 vs. 49<!--> <!-->±<!--> <!-->11 (<em>P</em>=n. s.) and 195<!--> <!-->±<!--> <!-->104 vs. 131<!--> <!-->±<!--> <!-->57<!--> <!-->mg/dl (<em>P</em>=n.s.). The estimated glomerular filtration rate basal medium was 37<!--> <!-->±<!--> <!-->14<!--> <!-->ml/min and one year: 37<!--> <!-->±<!--> <!-->13<!--> <!-->ml/min (<em>P</em>=n.s.) and urinary albumine/creatinine ratio, UA/Cr. was basal and one year: 679 vs. 523<!--> <!-->mg/g (<em>P</em>=n.s.).</p></div><div><h3>Conclusions</h3><p>The combination of simvastatin plus ezetimibe in CKD patients appears to be effective in lipid control at least in this follow-up period. No serious side effects associated have been observed. Demonstrating a reduction in cardiovascular risk associated with greater control of lipid levels requires a longer period of monitoring.</p></div>","PeriodicalId":100373,"journal":{"name":"Diálisis y Trasplante","volume":"36 1","pages":"Pages 1-7"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.dialis.2015.02.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120823801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}